<DOC>
	<DOCNO>NCT00755287</DOCNO>
	<brief_summary>This 3-arm study ass efficacy , safety tolerability taspoglutide compare insulin glargine patient insulin-naive type 2 diabetes mellitus inadequately control metformin sulphonylurea combination therapy . Patients randomize receive taspoglutide ( 10 mg weekly , 10mg weekly 4 week follow 20mg weekly ) insulin glargine ( start dose 10 IU/day ) ratio 1:1:1 addition continue prestudy metformin treatment . The anticipated time study treatment 2+ year , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Safety , Tolerability Effect Glycemic Control Taspoglutide Versus Insulin Glargine Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>adult patient , 1875 year age ; type 2 diabetes treat stable dose metformin sulphonylurea least 12 week ; Cpeptide ( fast ) &gt; =1.0ng/mL ; HbA1c &gt; =7.0 % &lt; =10.0 % screening ; BMI &gt; =25 ( &gt; 23 Asians ) &lt; =45kg/m2 screening ; stable weight +5 % least 12 week prior screen . history type 1 diabetes mellitus acute metabolic diabetic complication ketoacidosis hyperosmolar coma previous 6 month ; evidence clinically significant diabetic complication ; symptomatic poorly control diabetes ; clinically symptomatic gastrointestinal disease ; myocardial infarction , coronary artery bypass surgery , posttransplantation cardiomyopathy stroke within previous 6 month ; know hemoglobinopathy chronic anemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>